Sini powder ameliorates the inflammatory response in rats with stress-induced non-alcoholic fatty liver disease by inhibiting the nuclear factor kappa-B / pyrin domain-containing protein 3 pathway.


Journal

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
ISSN: 2589-451X
Titre abrégé: J Tradit Chin Med
Pays: China
ID NLM: 8211546

Informations de publication

Date de publication:
04 2020
Historique:
entrez: 4 4 2020
pubmed: 4 4 2020
medline: 18 8 2021
Statut: ppublish

Résumé

To evaluate the effectiveness of Sini powder for the treatment of non-alcoholic fatty liver disease (NAFLD) in rats and the molecular mechanisms involved. A rat model of stress-induced NAFLD was established by a combination of long-term tethering and feeding of a high-fat, high-calorie diet. These rats were then intragastrically administered with either simvastatin, Sini powder, or vehicle for 1 week. The body mass and field test scores for each group were recorded weekly. Serum aspartate aminotransferase and alanine aminotransferase activities, and triglyceride, total cholesterol, and free fatty acid concentrations were measured. Liver tissue histopathology was examined on hematoxylin and eosin-stained paraffin sections and oil red O-stained frozen sections. The hepatic mRNA expression of nuclear factor kappa-B (NF-κB), NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), apoptosis-associated speck-like protein containing CARD (ASC), and caspase-1 were measured by reverse transcription-polymerase chain reaction (RT-PCR). The hepatic protein concentrations of NF-κB and NLRP3, ASC, caspase-1, interleukin-1β (IL-1β), interleukin-6 (IL-6), and the serum concentrations of IL-1β and IL-6 were measured by enzyme-linked immunosorbent assay. Compared with the Blank group, rats in the Compound model group showed significant pathologic manifestations of NAFLD, and the expression of NF-κB, NLRP3, ASC, caspase-1, IL-1β and IL-6 were significantly higher (all P < 0.01). Both simvastatin and Sini powder significantly ameliorated the NAFLD pathology and the abnormal expression of NF-κB, NLRP3, ASC, caspase-1, IL-1β, and IL-6 (all P < 0.01). Sini powder inhibits the inflammatory response in rats with NAFLD, which is mediated by NF-κB/NLRP3, IL-1β, and IL-6, reduces the effects of psychological stress, and improves lipid metabolism. Therefore, Sini powder may be effective for the treatment of stress-related NAFLD through multiple mechanisms.

Identifiants

pubmed: 32242391
pii: 3013

Substances chimiques

Drugs, Chinese Herbal 0
Interleukin-1beta 0
NF-kappa B 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
Nlrp3 protein, rat 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

253-266

Auteurs

Jie Mu (J)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Fafeng Cheng (F)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Qingguo Wang (Q)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Xueqian Wang (X)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Wenxiang Zhu (W)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Chongyang Ma (C)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Xiangjun Yin (X)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Beida Ren (B)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Yajun Lian (Y)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Xin Du (X)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Haixia Zhang (H)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Shuling Liu (S)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Shuang Zhang (S)

Teaching and Research Office of Clinical Foundation of Chinese Medicine, School of Basic Medicine, Innovation Team of ""Basic Research on the Application of Classical Formulas"", Beijing University of Chinese Medicine, Beijing 100029, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH